

Joo Agostinho Machado-Neto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3802400/joao-agostinho-machado-neto-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88
papers

835
citations

17
h-index

25
g-index

99
ext. papers

1,062
ext. citations

3.9
avg, IF

4.03
L-index

#	Paper	IF	Citations
88	Effect of FKBP12-Derived Intracellular Peptides on Rapamycin-Induced FKBP-FRB Interaction and Autophagy.. <i>Cells</i> , 2022 , 11,	7.9	2
87	Phenformin increases early hematopoietic progenitors in the Jak2 murine model.. <i>Investigational New Drugs</i> , 2022 , 1	4.3	
86	Proteolytic processing in autophagy 2022 , 81-91		
85	Effects of trabectedin in the zebrafish <i>Danio rerio</i> : from cells to larvae. <i>Environmental Advances</i> , 2022 , 8, 100208	3.5	0
84	NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells.. <i>Investigational New Drugs</i> , 2022 , 1	4.3	0
83	Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2 driven cells.. <i>Toxicology in Vitro</i> , 2022 , 105384	3.6	
82	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. <i>Investigational New Drugs</i> , 2021 , 1	4.3	
81	Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. <i>Cancer Science</i> , 2021 ,	6.9	1
80	Expression of transforming growth factor β pathway components in chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.. <i>Transplant Immunology</i> , 2021 , 70, 101514	1.7	
79	Exploring redox vulnerabilities in JAK2-positive cellular models. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 , 43, 430-436	1.6	0
78	Synthetic cyclopenta[b]indoles exhibit antineoplastic activity by targeting microtubule dynamics in acute myeloid leukemia cells. <i>European Journal of Pharmacology</i> , 2021 , 894, 173853	5.3	2
77	Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 , 44, 124-124	1.6	1
76	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 35, 116085	3.4	3
75	Targeting glioma cells by antineoplastic activity of reversine. <i>Oncology Letters</i> , 2021 , 22, 610	2.6	1
74	Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation. <i>Small GTPases</i> , 2021 , 12, 20-26	2.7	2
73	DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy. <i>Cancer Genetics</i> , 2021 , 252-253, 6-24	2.3	9
72	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. <i>Investigational New Drugs</i> , 2021 , 39, 736-746	4.3	2

71	Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. <i>Cellular Oncology (Dordrecht)</i> , 2021 , 44, 1105-1117	7.2	3
70	Microemulsion for Prolonged Release of Fenretinide in the Mammary Tissue and Prevention of Breast Cancer Development. <i>Molecular Pharmaceutics</i> , 2021 , 18, 3401-3417	5.6	3
69	Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells. <i>Toxicology in Vitro</i> , 2021 , 76, 105207	3.6	0
68	AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. <i>Investigational New Drugs</i> , 2021 , 39, 1139-1149	4.3	2
67	Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas. <i>Molecules</i> , 2021 , 26,	4.8	1
66	NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2-positive myeloproliferative neoplasm cells. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 5	21	15
65	Irs1S57X Heterozygous Mutant Mice Display Normal Hematopoiesis and Phenotypic Features, While Homozygous Knockout Exhibit High Fetal or Postnatal Lethality. <i>Blood</i> , 2020 , 136, 33-34	2.2	
64	Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes. <i>BMB Reports</i> , 2020 , 53, 413-418	5.5	1
63	Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. <i>Cellular Oncology (Dordrecht)</i> , 2020 , 43, 1191-1201	7.2	2
62	Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. <i>Hematology, Transfusion and Cell Therapy</i> , 2020 , 42, 238-244	1.6	1
61	Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2 cells. <i>Investigational New Drugs</i> , 2020 , 38, 733-745	4.3	5
60	Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours. <i>Investigational New Drugs</i> , 2020 , 38, 899-908	4.3	5
59	Pradimicin-IRD exhibits antineoplastic effects by inducing DNA damage in colon cancer cells. <i>Biochemical Pharmacology</i> , 2019 , 168, 38-47	6	4
58	IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. <i>Cancer Letters</i> , 2019 , 456, 59-68	9.9	18
57	PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. <i>Cancer Genetics</i> , 2019 , 233-234, 56-66	2.3	5
56	Reversine exhibits antineoplastic activity in JAK2-positive myeloproliferative neoplasms. <i>Scientific Reports</i> , 2019 , 9, 9895	4.9	8
55	IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2689-2689	2.2	
54	Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion. <i>Journal of Cellular and Molecular Medicine</i> , 2019 , 23, 1562-1571	5.6	7

53	Metformin exerts multitarget antileukemia activity in JAK2-positive myeloproliferative neoplasms. <i>Cell Death and Disease</i> , 2018 , 9, 311	9.8	11
52	IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. <i>Hematology, Transfusion and Cell Therapy</i> , 2018 , 40, 92-95	1.6	
51	The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 959-966	6.9	3
50	Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival. <i>Applied Cancer Research</i> , 2018 , 38,	1.6	1
49	Serine peptidase inhibitor Kunitz type 2 (SPINT2) in cancer development and progression. <i>Biomedicine and Pharmacotherapy</i> , 2018 , 101, 278-286	7.5	16
48	IRS2 (insulin receptor substrate 2). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2018 ,	2.3	1
47	Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. <i>Clinics</i> , 2018 , 73, e5662.3	2.3	12
46	De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. <i>Scientific Reports</i> , 2017 , 7, 40707	4.9	19
45	Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. <i>Journal of Clinical Pathology</i> , 2017 , 70, 435-442	3.9	13
44	Stathmin 1 expression in plasma cell neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017 , 39, 183-185		
43	IRS1/βCatenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 1774-1781	4.7	12
42	Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells. <i>Heliyon</i> , 2017 , 3, e00405	3.6	6
41	Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017 , 39, 379-384		1
40	Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017 , 1863, 450-461	6.9	18
39	BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine. <i>Haematologica</i> , 2016 , 101, e445-e448	6.6	13
38	Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. <i>Diagnostic Pathology</i> , 2016 , 11, 28	3	10
37	Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis. <i>Blood Cells, Molecules, and Diseases</i> , 2016 , 60, 74-7	2.1	4
36	Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells. <i>Oncotarget</i> , 2016 , 7, 68339-68349	3.3	54

35	CATS (FAM64A) abnormal expression reduces clonogenicity of hematopoietic cells. <i>Oncotarget</i> , 2016 , 7, 68385-68396	3.3	14
34	IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. <i>Oncotarget</i> , 2016 , 7, 6948-59	3.3	12
33	Reversine triggers mitotic catastrophe and apoptosis in K562 cells. <i>Leukemia Research</i> , 2016 , 48, 26-31	2.7	11
32	Reactive oxygen species overload promotes apoptosis in JAK2V617F-positive cell lines. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016 , 38, 179-81		2
31	Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016 , 38, 368-370		1
30	Differential profile of PIP4K2A expression in hematological malignancies. <i>Blood Cells, Molecules, and Diseases</i> , 2015 , 55, 228-35	2.1	5
29	Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 2015 , 51, 2076-85	7.5	17
28	Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015 , 37, 211-4		2
27	Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015 , 1853, 388-95	4.9	8
26	Elevated hypercoagulability markers in hemoglobin SC disease. <i>Haematologica</i> , 2015 , 100, 466-71	6.6	22
25	ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015 , 1853, 583-93	4.9	17
24	ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth. <i>European Journal of Cancer</i> , 2015 , 51, 252-9	7.5	18
23	Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2015 , 94, 413-8	3.8	17
22	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. <i>Oncotarget</i> , 2015 , 6, 29573-84	3.3	16
21	Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. <i>Leukemia Research</i> , 2014 , 38, 251-7	2.7	25
20	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. <i>Leukemia Research</i> , 2014 , 38, 1245-51	2.7	38
19	PIPKIII α s widely expressed in hematopoietic-derived cells and may play a role in the expression of alpha- and gamma-globins in K562 cells. <i>Molecular and Cellular Biochemistry</i> , 2014 , 393, 145-53	4.2	2
18	ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. <i>Experimental Cell Research</i> , 2014 , 324, 137-45	4.2	37

17	Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion. <i>Stem Cells and Development</i> , 2014 , 23, 1109-20	4.4	5
16	YAP1 expression in myelodysplastic syndromes and acute leukemias. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2413-5	1.9	8
15	Stathmin 1 in normal and malignant hematopoiesis. <i>BMB Reports</i> , 2014 , 47, 660-5	5.5	30
14	Stathmin 1, a therapeutic target in esophageal carcinoma?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 6461-2	1.7	
13	Gene expression analysis of the Brazilian type of hereditary persistence of fetal hemoglobin: identification of genes that could be related to β globin activation. <i>Hemoglobin</i> , 2013 , 37, 516-35	0.6	3
12	FMNL1 promotes proliferation and migration of leukemia cells. <i>Journal of Leukocyte Biology</i> , 2013 , 94, 503-12	6.5	32
11	IL10 inversely correlates with the percentage of CD8+ cells in MDS patients. <i>Leukemia Research</i> , 2013 , 37, 541-6	2.7	13
10	ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013 , 1832, 365-74	6.9	39
9	ARHGAP21 protein, a new partner of β tubulin involved in cell-cell adhesion formation and essential for epithelial-mesenchymal transition. <i>Journal of Biological Chemistry</i> , 2013 , 288, 2179-89	5.4	38
8	PTK2 and PTPN11 expression in myelodysplastic syndromes. <i>Clinics</i> , 2013 , 68, 1371-5	2.3	
7	Downregulation of IRS2 in myelodysplastic syndrome: a possible role in impaired hematopoietic cell differentiation. <i>Leukemia Research</i> , 2012 , 36, 931-5	2.7	9
6	Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1967-70	15.4	33
5	ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells. <i>FEBS Letters</i> , 2012 , 586, 4311-8	3.8	20
4	Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients. <i>Leukemia Research</i> , 2012 , 36, 1300-3	2.7	15
3	Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome. <i>Neoplasia</i> , 2012 , 59, 530-5	3.3	4
2	Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011 , 1813, 1404-149	4.9	22
1	Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. <i>Clinics</i> , 2011 , 66, 793-9	2.3	3